- Newmarket was founded in London in 2021
- Baird Capital invests in B2B technology & services-focused companies
- Baird Capital is the direct private investment arm of Robert W. Baird & Co
Baird Capital has made an investment in Newmarket Strategy.
Founded in London in 2021, Newmarket is an independent life sciences consultancy and market access company. Clients include global pharmaceuticals and biotech, med-tech, diagnostics, digital health, private equity and healthcare services providers.
The investment will support the company’s growth in the pharmaceutical services and healthcare advisory sector, a statement read.
“The team brings a high level of expertise, and the services they provide address a critical need across the clients they serve,” said Michael Holgate, partner at Baird Capital, in a statement. “This investment in Newmarket follows a number of previous investments that we have made in the Pharma Services segment including Campbell Alliance, Prescient and Blue Matter.”
Baird Capital invests in B2B technology & services-focused companies. Founded in 1989, Baird Capital is the direct private investment arm of Robert W. Baird & Co.
